ALLOX closes a $10.5 million seed round for its AI and high-throughput biophysics allosteric drug discovery platform

Barcelona-based ALLOX closed a US$10.5m (EUR 9.4m) seed round led by Asabys (Sabadell Asabys II), with CDTI (SICC Innvierte) and the Institut Catala de Finances, and appointed Morten Graugaard independent board chair. Proceeds scale its high-throughput biophysics platform and AI models that predict therapeutic hotspots from function-first datasets, and a pipeline of small molecules against hard-to-drug protein-protein interactions and transcription factors. Announced 29 October 2026.